[Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].

Huijie Fan(Shanxi University), Xingya Li(Zhengzhou University), Jing Yuan(Sun Yat-sen University), Yongxu Jia(First Affiliated Hospital of Zhengzhou University), Yihui Ma(Wuhan University), Jingjing Wu(First Affiliated Hospital of Zhengzhou University)
PubMed
January 8, 2019
10.3760/cma.j.issn.0376-2491.2019.02.005
Cited by 5

Related Papers

High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene
|Cancer Cell|2004|379
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
|The Lancet Oncology|2020|193
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2021|183
Inhibition of NOTCH Signaling by Gamma Secretase Inhibitor Engages the RB Pathway and Elicits Cell Cycle Exit in T-Cell Acute Lymphoblastic Leukemia Cells
|Cancer Research|2009|165